Markers of effectiveness of preoperative taxane-chemotherapy for locally advanced breast cancer
Vol. 70 No. 1 (2024), Articles
Vol. 70 No. 1 (2024)

Markers of effectiveness of preoperative taxane-chemotherapy for locally advanced breast cancer

Articles
https://doi.org/10.37469/0507-3758-2013-59-3-363-368
Published 15.12.2013
N.N.Petrov Research Institute of Oncology
N.N.Petrov Research Institute of Oncology
N.N.Petrov Research Institute of Oncology
N.N.Petrov Research Institute of Oncology
N.N.Petrov Research Institute of Oncology
N.N.Petrov Research Institute of Oncology
N.N.Petrov Research Institute of Oncology
N.N.Petrov Research Institute of Oncology
N.N.Petrov Research Institute of Oncology
I.P.Pavlov State Medical University
N.N.Petrov Research Institute of Oncology
N.N.Petrov Research Institute of Oncology
N.N.Petrov Research Institute of Oncology
N.N.Petrov Research Institute of Oncology
N.N.Petrov Research Institute of Oncology
N.N.Petrov Research Institute of Oncology
N.N.Petrov Research Institute of Oncology
N.N.Petrov Research Institute of Oncology
##article.numberofdownloads## 133
##article.numberofviews## 193
PDF (Русский)

Keywords

TOP2a

How to Cite

, , , , , , , , , , , , , , , , , & . (2013). Markers of effectiveness of preoperative taxane-chemotherapy for locally advanced breast cancer. Voprosy Onkologii, 70(1), 363–368. https://doi.org/10.37469/0507-3758-2013-59-3-363-368
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Abstract

The absolute sensitivity signs of breast cancer to the drug have not yet been developed. Data from clinical trials on the study of experimental laboratory predictive markers of chemosensitivity: TOP2a (topoisomerase 2-alpha), P-tubulin (subunit of dimeric protein tubulin), and BRCA1 (breast cancer 1) are contradictory and not numerous. Analysis of the results by the end of the clinical trial will allow examining the correlation between the effectiveness of preoperative taxane-chemotherapy and the level of experimental and standard molecular markers that is important for development of algorithm of treatment tactics for patients with locally advanced breast cancer.
https://doi.org/10.37469/0507-3758-2013-59-3-363-368
##article.numberofdownloads## 133
##article.numberofviews## 193
PDF (Русский)

References

Имянитов Е.Н. Наследственный рак молочной железы // Практ. онкол. — 2010. — Т 11. -№ 4. — С. 258-264.

Имянитов Е.Н., Хансон К.П. Молекулярная онкология: клинические аспекты/ / СПб.: СПбМАПО,- 2007. — 211 с.

Семиглазов В.Ф. Стратегические и практические подходы к решению проблемы рака молочной железы // Вопр. онкол. — 2012. — Т. 58. — № 2 — С. 148-152.

Семиглазов В.Ф., Манихас А.Г., Семиглазова Т.Ю. и др. Неоадъювантная системная терапия рака молочной железы // Руководство для врачей. — СПб.: Аграф. — 2012. — 112 с.

Семиглазов В.Ф., Семиглазов В.В., Манихас А.Г. Рак молочной железы. Химиотерапия и таргетная терапия // М.: МЕДпресс-информ.- 2012.-360 с.

Bonadonna G., Veronesi U., Brambilla C. et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more // J Natl Cancer. — 1990. — Vol. 82. — Р 1539-1545.

Brase J., Schmidt M., Fischbach T. et al. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction // Clin. Cancer Res. — 2010. — Vol. 16 — № 8. — P 23912401.

Burkhart C., Kavallaris M., Horwitz S. The role of p-tubulin isotypes in resistance to antimitotic drugs // Biochim Biophys Acta. — 2001. — Vol. 1471 (2). — P. 1-9.

Byrski T., Gronwald J., Huzarski T. et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy // J. Clin. Oncol. — 2010. — Vol. 28.- № 3. — P 375-379.

Miller I.D., Payne S., Ogston K.N. A new gistological grading system to assess response of breast cancer to primary chemotherapy // Int J Oncol. -2002. — № 20 (4). — Р 791-796.

Oakman C., Moretti E., Galardi F. et al. The role of topoisomerase II alpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients // Cancer Treat. Rev. — 2009. — Vol. 35. — № 8. — P. 662-667.

Paradiso A., Mangia A., Chiriatti A. et al. Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer // Ann. Oncol. — 2005. — Vol. 16 (4). — P. 14-19.

All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...